Aymaan Zaheer

Aymaan Zaheer i

Translational Health Science and Technology Institute - Faridabad / India
Medical and Health Sciences / Immunology
AD Scientific Index ID: 5383436
अनुवाद स्वास्थ्य विज्ञान और प्रौद्योगिकी संस्थान
person_outline Aymaan Zaheer's MOST POPULAR ARTICLES
1-) Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B. 1.617. 2) variant surge in India: a test-negative, case-control study and a …R Thiruvengadam, A Awasthi, G Medigeshi, S Bhattacharya, S Mani, ...The Lancet Infectious Diseases 22 (4), 473-482, 2022942022
2-) Safety, tolerability and immunogenicity of Biological E’s CORBEVAX™ vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 …S Thuluva, V Paradkar, SR Gunneri, V Yerroju, RR Mogulla, PV Suneetha, ...Vaccine 40 (49), 7130-7140, 2022242022
3-) Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine compared to COVISHIELD™(ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized …S Thuluva, V Paradkar, SR Gunneri, V Yerroju, R Mogulla, PV Suneetha, ...Human Vaccines & Immunotherapeutics 19 (1), 2203632, 2023142023
4-) Cellular immune responses are preserved and may contribute to Chadox1 ChAdOx1 nCoV-19 vaccine effectiveness against infection due to SARS-CoV-2 B· 1· 617· 2 delta variant …R Thiruvengadam, A Awasthi, G Medigeshi, S Bhattacharya, S Mani, ...132021
5-) Immunogenic superiority and safety of Biological E’s CORBEVAX™ vaccine compared to COVISHIELD™(ChAdOx1 nCoV-19) vaccine studied in a phase III, single blind, multicenter …S Thuluva, V Paradkar, K Turaga, SR Gunneri, V Yerroju, R Mogulla, ...Medrxiv, 2022.03. 20.22271891, 2022112022